Usc Norris Comprehensive Cancer Center (Nccc)

Los Angeles, California 90089-1019

3 studies enrolling now · 6 studies all time

What they study most

Advanced Cancer, Advanced Colorectal Cancer, Advanced Esophageal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor, Metastatic Solid Tumors, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Studies at this site

• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors — Recruiting now
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification — Stopped early
• A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors — Stopped early